5 Best Longevity and Anti-Aging Stocks to Buy

2. Novo Nordisk A/S (NYSE:NVO)

Short Percentage of Shares Outstanding: 0.51%

On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares.

Earlier, on June 11, Novo Nordisk A/S (NYSE:NVO) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency approved the Wegovy pill as an adjunct to a reduced-calorie diet and increased physical activity. The approval makes the therapy the first oral GLP-1 receptor agonist authorized for weight management in adults living with obesity or overweight who also have at least one weight-related medical condition. The decision was supported by data from the Phase 3 OASIS 4 clinical trial and expands Novo Nordisk’s obesity treatment portfolio by offering patients a non-injectable alternative to existing therapies.

Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in chronic conditions like diabetes and obesity. It is primarily known for developing lifesaving GLP-1 therapies like Ozempic and Wegovy, but it also targets the underlying metabolic and cardiovascular diseases that reduce lifespan.